Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.74 USD
Change Today +0.06 / 1.06%
Volume 18.9K
ITEK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Munich
As of 4:00 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

inotek pharmaceuticals corp (ITEK) Snapshot

Open
$5.76
Previous Close
$5.68
Day High
$5.80
Day Low
$5.67
52 Week High
02/18/15 - $6.20
52 Week Low
04/23/15 - $4.68
Market Cap
93.7M
Average Volume 10 Days
49.0K
EPS TTM
--
Shares Outstanding
16.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOTEK PHARMACEUTICALS CORP (ITEK)

Related News

No related news articles were found.

inotek pharmaceuticals corp (ITEK) Related Businessweek News

No Related Businessweek News Found

inotek pharmaceuticals corp (ITEK) Details

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma. The company’s lead product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism, as well as for optic neuropathy. Its product pipeline also includes Trabodenoson plus Latanoprost, a fixed-dose combination prostaglandin analogue, which has completed the Phase II clinical trials for IOP-lowering in patients who have previously had inadequate response to latanoprost. Inotek Pharmaceuticals Corporation was founded in 1999 and is headquartered in Lexington, Massachusetts.

8 Employees
Last Reported Date: 05/14/15
Founded in 1999

inotek pharmaceuticals corp (ITEK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $154.1K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $102.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $447.3K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $390.5K
Compensation as of Fiscal Year 2014.

inotek pharmaceuticals corp (ITEK) Key Developments

Inotek Pharmaceuticals Corporation Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Inotek Pharmaceuticals Corporation reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $3,049,000 against $1,712,000 a year ago. Net loss was $1,462,000 or $0.21 per basic and diluted share against $2,148,000 or $3.08 per basic and diluted share a year ago.

Devang Kantesaria Not to Stand for Re-Election to Inotek Pharmaceuticals Corporation Board of Directors

On April 28, 2015, Devang Kantesaria informed the Board of Directors of Inotek Pharmaceuticals Corporation that he will not stand for re-election to the Board of Directors when his term expires at the company’s upcoming 2015 annual meeting of stockholders (Annual Meeting) and he tenders his resignation as a member of the Board of Directors of the company upon the conclusion of the Annual Meeting. Mr. Kantesaria’s decision not to stand for re-election did not result from any disagreement with the company on any matter relating to the company’s operations, policies or practices.

Inotek Pharmaceuticals Corporation Reports Earnings Results for the Year Ended December 31, 2014

Inotek Pharmaceuticals Corporation reported earnings results for the year ended December 31, 2014. For the year, loss from operations was $7.704 million against $6.654 million a year ago. Net loss was $9.531 million or $13.52 against $7.616 million a year ago. Net loss per share attributable to common stockholders, basic and diluted was $13.52 against net income per share attributable to common stockholders, basic and diluted of $10.05 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITEK:US $5.74 USD +0.06

ITEK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITEK.
View Industry Companies
 

Industry Analysis

ITEK

Industry Average

Valuation ITEK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOTEK PHARMACEUTICALS CORP, please visit www.inotekcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.